Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia (ELUT) will present and meet investors at the H.C.
Rhea-AI Summary
Elutia (ELUT) will present and meet investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15–16, 2026.
Chief Executive Officer Dr. Randy Mills, Chief Scientific Officer Dr. Michelle Williams, and Chief Financial Officer Matthew Ferguson will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries through its drug-eluting biomatrix technology. The live presentation, replacing a previously announced pre-recorded talk, is scheduled for 4:30 p.m. Eastern Time on Tuesday, September 15, 2026, and will be accessible online. Elutia will also host one-on-one investor meetings during the conference.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 15–16, 2026.
During the presentation, management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries—one of the most significant challenges facing patients and surgeons—through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.
The presentation will begin at 4:30 pm Eastern Time on Tuesday, September 15, 2026, and can be accessed live here. This presentation will take the place of our previously announced pre-recorded presentation. Elutia will also host one-on-one meetings with investors on September 15–16, 2026. To schedule a one-on-one meeting, conference attendees should visit H.C. Wainwright.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Elutia Investor Relations
ir@elutia.com
FAQ
Who from Elutia will present at the H.C. Wainwright 28th Annual Global Investment Conference?
The presenters will be Dr. Randy Mills, Chief Executive Officer; Dr. Michelle Williams, Chief Scientific Officer; and Matthew Ferguson, Chief Financial Officer.
When and where is Elutia’s live presentation scheduled during the conference?
The live presentation is scheduled for 4:30 p.m. Eastern Time on Tuesday, September 15, 2026, at the Lotte New York Palace Hotel in New York City, as part of the H.C. Wainwright 28th Annual Global Investment Conference.
How can investors access Elutia’s presentation and schedule one-on-one meetings?
The presentation can be accessed live online via the conference platform linked in the announcement, and conference attendees can schedule one-on-one meetings with Elutia on September 15–16, 2026, by visiting H.C. Wainwright.
What topic will Elutia’s management focus on in the presentation?
Management will discuss how Elutia is working to address post-surgical infection in plastic and reconstructive surgeries through its drug-eluting biomatrix technology, which is designed to support safer, more reliable reconstructive outcomes.
What change was made to Elutia’s previously planned conference presentation format?
The company states that this live presentation will take the place of its previously announced pre-recorded presentation for the conference.